In a small sample of participants with hepatic steatosis, ARO-ANG3 also decreased atherogenic lipoproteins, and, notably, no increase in liver fat was observed after repeat dosing, with most participants showing a numerical decline in liver fat content18. The gene discussed is CYP19A1; the disease is fatty liver disease.